aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
21 déc. 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
12 nov. 2020 16h05 HE
|
aTyr Pharma, Inc.
Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational New Drug...
aTyr Pharma Announces Publication in the Journal mAbs
11 nov. 2020 07h00 HE
|
aTyr Pharma, Inc.
Peer-reviewed paper supports aTyr’s antibody program. Research conducted in collaboration with AbCellera Biologics, Inc. SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:...
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline
10 nov. 2020 07h00 HE
|
aTyr Pharma, Inc.
Discovery advances the understanding of extracellular tRNA synthetase pathways. Findings may contribute to the development of new therapeutics to treat cancer and fibrosis. SAN DIEGO, Nov. 10,...
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST
05 nov. 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Research Collaboration with Medical University of South Carolina
29 oct. 2020 07h00 HE
|
aTyr Pharma, Inc.
Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology. SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc....
aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th
27 oct. 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
26 oct. 2020 07h00 HE
|
aTyr Pharma, Inc.
Topline results are expected in the fourth quarter of 2020. Trial evaluating the preliminary safety and efficacy of ATYR1923 vs placebo has exceeded enrollment. SAN DIEGO, Oct. 26, 2020 (GLOBE...
aTyr Pharma to Participate in October Virtual Investor Events
07 oct. 2020 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
15 sept. 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...